Clinical trial
A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period
This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
| Category | Value |
|---|---|
| Date last updated at source | 2016-08-27 |
| Study type(s) | Interventional |
| Expected enrolment | 1346 |
| Study start date | 2012-07-01 |
| Estimated primary completion date | 2019-08-01 |